Cholestyramine-induced hyperchloremic metabolic acidosis

P. J. Scheel, A. Whelton, K. Rossiter, A. Watson

Research output: Contribution to journalArticle

Abstract

Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis.

Original languageEnglish (US)
Pages (from-to)536-538
Number of pages3
JournalJournal of Clinical Pharmacology
Volume32
Issue number6
StatePublished - 1992

Fingerprint

Cholestyramine Resin
Acidosis
Anion Exchange Resins
Spironolactone
Hypercholesterolemia
Renal Insufficiency
Diarrhea
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Scheel, P. J., Whelton, A., Rossiter, K., & Watson, A. (1992). Cholestyramine-induced hyperchloremic metabolic acidosis. Journal of Clinical Pharmacology, 32(6), 536-538.

Cholestyramine-induced hyperchloremic metabolic acidosis. / Scheel, P. J.; Whelton, A.; Rossiter, K.; Watson, A.

In: Journal of Clinical Pharmacology, Vol. 32, No. 6, 1992, p. 536-538.

Research output: Contribution to journalArticle

Scheel, PJ, Whelton, A, Rossiter, K & Watson, A 1992, 'Cholestyramine-induced hyperchloremic metabolic acidosis', Journal of Clinical Pharmacology, vol. 32, no. 6, pp. 536-538.
Scheel PJ, Whelton A, Rossiter K, Watson A. Cholestyramine-induced hyperchloremic metabolic acidosis. Journal of Clinical Pharmacology. 1992;32(6):536-538.
Scheel, P. J. ; Whelton, A. ; Rossiter, K. ; Watson, A. / Cholestyramine-induced hyperchloremic metabolic acidosis. In: Journal of Clinical Pharmacology. 1992 ; Vol. 32, No. 6. pp. 536-538.
@article{48b206d2c4344981b44e2a8120383fba,
title = "Cholestyramine-induced hyperchloremic metabolic acidosis",
abstract = "Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis.",
author = "Scheel, {P. J.} and A. Whelton and K. Rossiter and A. Watson",
year = "1992",
language = "English (US)",
volume = "32",
pages = "536--538",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Cholestyramine-induced hyperchloremic metabolic acidosis

AU - Scheel, P. J.

AU - Whelton, A.

AU - Rossiter, K.

AU - Watson, A.

PY - 1992

Y1 - 1992

N2 - Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis.

AB - Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis.

UR - http://www.scopus.com/inward/record.url?scp=0026777553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026777553&partnerID=8YFLogxK

M3 - Article

C2 - 1634640

AN - SCOPUS:0026777553

VL - 32

SP - 536

EP - 538

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 6

ER -